2 stocks to Buy in the ASX's worst-performing sector

What seems a fairly typical year for the ASX 200 on the surface hides its share of surprises underneath. 

And for one (or two) sectors in particular, 2025 has been a year to forget. 

Despite boasting some of the ASX's best growth stories of recent years, Healthcare looks set to end the year at the bottom of the pile.

It's a sector hit hard by notable names underperforming and still reeling from the uncertainty created by Trump's tariff policy.

The headline grabber has been CSL (ASX: CSL), which has endured a fairly disastrous calendar year.

But greenshoots are still there and tailwinds are growing, according to fundies. In its recent 2026 sector outlook, Morgans upgraded the sector to Overweight, and VanEck's Cameron McCormack recently wrote for Livewire that "policy clarity, increased M&A, and solid earnings have made global healthcare attractive for investors seeking to fortify portfolios."

But what ASX names should you be looking at to play the Healthcare recovery? Here are two stocks currently rated a Strong Buy, according to Market Index's broker consensus tool.

1. Telix Pharmaceuticals (ASX: TLX)

Biopharmacetuical company Telix was actually one of our readers' most-tipped growth stocks for 2025, but a series of regulatory and legal issues has seen it sell off by more than 40% so far in 2025, even as results looked solid. 

Q3 group revenue hit $206 million, up 53% YoY, and FY25 guidance was increased from US$800m to US$820m, and upcoming developments suggest room for more upside. 

A recent study of its imaging agent Zircaix showed it could help avoid biopsy in 23% of cases, and change clinical management in a further 49%. Morgan Stanley expect the product to launch in 2H26, and believe it should have a risk-weighted contribution to the TLX share price of $2.10 a share. It is targeting a $25.40 share price.

Citi identified two other near-term catalysts for Telix: FDA resubmission of its brain cancer imaging agent Pixclara, and an update on its phase 3 trial for its prostate cancer drug TLX591. Yesterday Telix also announced a partnership with cancer care company Varian.  

Currently trading at $14 per share, the consensus price target is $27.50, suggesting a 95% potential return from current prices. 

2. Regis Healthcare (ASX: REG)

In contrast to Telix, Regis Healthcare has been one of the few solid performers in the Healthcare sector in 2025.

The aged care operator is up 27% year-to-date, but sold off from more than $9 a share to around $6 after FY26 guidance came in below consensus. It has since recovered to $7.50 and maintains Buy ratings across the board from brokers, even if some have revised their targets downward.

Ord Minnett maintains the highest price target, at $8.50 per share, and suggests longer-term demand in the industry remains highly favourable, even as sector profitability is under pressure. 

While Macquarie was one of handful of brokers to lower its target, it argued that Regis' balance sheet could fund further acquisitions, after adding 13 new aged care homes to its portfolio over the last two years. 

At its recent AGM presentation, Regis maintained FY26 underlying EBITDA of $130-135m, against $134.6m consensus target, confirmed a net cash holding of $99m and reaffirmed its FY28 bed target of 10,000 beds. 

REG is currently trading at $7.51 per share, with a consensus price target of $8.20, suggesting 9% upside potential.